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block to cell differentiation
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Reproducibility Project: Cancer Biology*
1Cancer Metabolism Facility, Sanford Burnham Prebys Medical Discovery Institute,
La Jolla, United States; 2Functional Genomics Core, Sanford Burnham Prebys
Medical Discovery Institute, La Jolla, United States; 3Washington University School
of Medicine, St Louis, United States
Abstract The Reproducibility Project: Cancer Biology seeks to address growing concerns about
reproducibility in scientific research by conducting replications of selected experiments from a
number of high-profile papers in the field of cancer biology. The papers, which were published
between 2010 and 2012, were selected on the basis of citations and Altmetric scores (Errington
et al., 2014). This Registered Report describes the proposed replication plan of key experiments
from “IDH mutation impairs histone demethylation and results in a block to cell differentiation” by
Lu and colleagues, published in Nature in 2012 (Lu et al., 2012). The experiments that will be
replicated are those reported in Figures 1B, 2A, 2B, 2D and 4D. Lu and colleagues demonstrated
that expression of mutant forms of IDH1 or IDH2 caused global increases in histone methylation
and increased levels of 2 hydroxyglutarate (Figure 1B). This was correlated with a block in
differentiation (Figures 2A, B and D). This effect appeared to be mediated by the histone
demethylase KDM4C (Figure 4D). The Reproducibility Project: Cancer Biology is a collaboration
between the Center for Open Scienceand Science Exchange, and the results of the replications will
be published by eLife.
DOI: 10.7554/eLife.10860.001
Introduction
Mutations in the metabolic proteins IDH1 and IDH2 are associated with gliomas, acute myeloid leu-
kemias, chondrosarcomas, intrahepatic cholangiocarcinomas, lymphomas, melanomas and colon,
thyroid and prostate cancers (for review, see Krell et al., 2013). Previous work has shown that these
mutations change the specificity of the reaction catalyzed by IDH proteins; instead of producing a-
ketoglutarate from isocitrate, they produce 2-hydroxyglutarate (2HG), a metabolite that can have
oncogenic effects (Krell et al., 2013; McKenney and Levine, 2013; Ward et al., 2010; Xu et al.,
2011; Zhang et al., 2013). Lu and colleagues expand upon this work to identify a potential mecha-
nism for how 2HG can effect major changes in cell behavior. They present evidence that 2HG inter-
feres with global demethylation that is required for progenitor cells to complete terminal
differentiation. Transfection of 3T3-L1 cells with the mutant forms of IDH1 and IDH2 that produce
2HG lead to an increase in global methylation levels and prevented normal in vitro differentiation
into adipocytes. The 2HG-sensitive histone demethylase KDM4C appeared to be required for this
process, as knockdown of KDM4C recapitulated the phenotype of 2HG production. Examination of
glioma samples showed a correlation between IDH mutation status and level of overall methylation
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(Lu et al., 2012). Taken together, Lu and colleagues’ findings help explain how mutations in IDH1
and IDH2 potentially interface with cancer development and progression.
In Figure 1B, Lu and colleagues examined the effects of mutations in IDH1 and IDH2 on global
levels of methylation by transfecting mutant and wild type forms of the genes into 293T cells and
using Western blot to assess the levels of various methylation markers. They also confirmed that
introduction of the mutated forms of IDH1 and IDH2 correlated with increased intracellular levels of
the oncometabolite 2HG. Their findings suggest that mutations in IDH1 and IDH2 correlate with
increased levels of many methylation markers, and this key finding is replicated in Protocol 1.
In order to understand the effects of hypermethylation more fully, Lu and colleagues turned to an
in vitro model of differentiation; when treated with appropriate signals, 3T3-L1 cells undergo epige-
netic changes required for them to differentiation into adipocytes. In Figure 2A and B, they transfect
undifferentiated 3T3-L1 cells with the wild type and mutant forms of IDH2 and assess the cells’ ability
to differentiate into adipocytes, as determined by staining for lipid droplets with Oil-Red-O. While
differentiated 3T3-L1 cells transfected with vector only or wild type IDH2 showed robust Oil-Red-O
staining, cells transfected with mutant IDH2 did not, indicating a block in differentiation. qRT-PCR
confirmed that cells transfected with mutant IDH variants did not express high levels of known adi-
pocyte markers (Figure 2D). This key finding will be replicated in Protocol 2.
Lu and colleagues identified a histone demethylase, KDM4C, expressed as 3T3-L1 differentiation
progressed, that appeared to be sensitive to 2HG. In Figure 4D, they use siRNAs to knock down lev-
els of KDM4C in differentiating 3T3-L1 cells. Western blot analysis and Oil-Red-O staining confirmed
that loss of KDM4C increased global methylation levels and inhibited differentiation. This key finding
will be replicated in Protocol 3.
Several aspects of Lu’s findings have been corroborated by other work. Multiple groups have
demonstrated that perturbations in IDH proteins alter methylation levels; overexpression of the
IDH1R132H allele in human tumor cells lines increased global histone methylation levels
(Duncan et al., 2012), exogenous IDH2R140Q increased methylation levels in erythroleukemia pro-
genitor cells (Kernytsky et al., 2015) and an immortalized astrocyte cell line expressing IDH1R132H
also demonstrated increased levels of methylation (Turcan et al., 2012). Members of the Thompson
lab (authors of this study) have confirmed that expression of mutant variants of IDH proteins in 3T3-
L1 cells blocked differentiation into adipocytes (Londono Gentile et al., 2013; Ward et al., 2013).
Sasaki and colleagues have shown that mutant IDH1 expression increased levels of methylation in
mice (Sasaki et al., 2012), while Akbay and colleagues published a similar observation for mutant
forms of IDH2 (Akbay et al., 2014). This effect may even hold true for human patients, as there is a
marked increase in H3K9me3 levels associated with IDH mutations in oligodendromas and high
grade astrocytomas (Venneti et al., 2013).
Materials and methods
Unless otherwise noted, all protocol information was derived from the original paper, references
from the original paper, or information obtained directly from the authors. An asterisk (*) indicates
data or information provided by the Reproducibility Project: Cancer Biology core team. A hashtag
(#) indicates information provided by the replicating lab.
Protocol 1: Assessing the methylation status and 2HG production of
293T cells transfected with mutant forms of IDH1 and IDH2
This protocol describes how to transfect 293T cells with wild-type and mutant forms of IDH1 and
IDH2 and assess levels of global methylation and 2HG production, as seen in Figure 1B and Supple-
mental Figure 1.
Sampling
. Experiment will be repeated a total of 6 times for a minimum power of 80%. The metabolite
data is qualitative, thus to determine an appropriate number of replicates to initially perform,
sample sizes based on a range of potential variance was determined.
 See "power alculations’ for details.
 The metabolite data displayed in the bottom of Figure 1B were derived from Figure 3B of
Figueroa and colleagues (Figueroa et al., 2010).
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. Each experiment consists of five cohorts:
 Cohort 1: 293T cells transfected with vector only
 Cohort 2: 293T cells transfected with wild-type IDH1
 Cohort 3: 293T cells transfected with IDH1R132H
 Cohort 4: 293T cells transfected with wild type IDH2
 Cohort 5: 293T cells transfected with IDH2R172K
. Each cohort is then examined for methylation status by Western blot and levels of 2HG pro-
duction by GC-MS.
Materials and reagents
Reagent Type Manufacturer Catalog # Comments
10 cm tissue culture dishes Labware Thermo Scientific 130182 Original unspecified
Bradford Assay Kit Reporter assay Bio-Rad 500-0201EDU Original unspecified
DMEM Cell culture Corning 15013 CV Replaces original from Invitrogen
Endo-free plasmid maxiprep kit Kit Qiagen 12362 Original unspecified
Fetal bovine serum (FBS) Cell culture CellGro 10437-028 Original cat # unspecified
293T cells Cell line ATCC CRL-3216 Original source unspecified
HRP-conjugated donkey
anti-rabbit secondary
Antibody GE Healthcare NA934V
HRP-conjugated sheep
anti-mouse secondary
Antibody GE Healthcare NA931V
IDH1 ORF clone Nucleic acid OriGene RC210582 Replaces ATCC plasmid
in pCMV-Sport6
IDH1R132H ORF clone Nucleic acid OriGene RC400096 Original generated
by authors
IDH2 ORF clone Nucleic acid OriGene RC201152 Replaces Invitrogen
plasmid in pOTB7







Western blot reagent Life Technologies LC2006 Original source unspecified
Nonfat milk Western blot reagent Carnation Original source unspecified
NuPAGE 4-12% precast
gradient gel
Western blot reagent Invitrogen WG1401BOX Original source unspecified
PierceÔ ECL Plus
Western Blotting Substrate
Western blot reagent Life Technologies 32132 Original unspecified
pLPC vector plasmid
(pLPC H-Ras V12)
Nucleic acid Addgene 18741 Original source unspecified
Ponceau stain Chemical SIGMA P7170-1L Original unspecified
Protease Inhibitor
Cocktail,
Inhibitor Sigma-Aldrich P8340 Original unspecified
Rabbit IgG monoclonal
anti-H3









Antibody Cell Signaling Technology 9757
Continued on next page
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Continued
Reagent Type Manufacturer Catalog # Comments
Rabbit polyclonal
anti-H3K9me2







TBS + Tween 20 Buffer Fisher Scientific BP-2471-1 Original source unspecified
XCell II blot module Instrument Life Technologies EI9051 Original unspecified
Acetonitrile, HPLC
grade
Chemical Spectrum HP412 Original source unspecified
Chloroform Chemical Fisher C606-4 Original unspecified
D-alpha-hydroxyglutaric
acid disodium salt (2HG)
Chemical Santa Cruz Biotechnology Sc-227739 Replaces original from Sigma
Methanol, HPLC grade Chemical MP 300141 Original source unspecified
N-methyl-N-tert-butyldimethylsilyl
trifluoroacetamide (MTBSTFA)
Chemical Soltec Ventures GC102 Replaces original
from Regis




Reporter assay Bio-Rad 500-0205 Original unspecified
Lipofectamine 2000 Cell culture Life Technologies 11668027 Original cat # unspecified
Procedure
Note: 293T cells are maintained in DMEM with 10% FBS at 37˚C/5% CO2 All cells will be sent for
STR profiling and mycoplasma testing.
. Using the pLPC backbone and the OriGene ORF clones, clone in the sequences for wild-type





. Prep each vector using an endo-free maxiprep kit according to the manufacturer’s instructions.
. Confirm plasmid identity by sequencing insert and vector integrity by agarose gel
electrophoresis.
1. Note; OriGene ORF clones are shipped with sequencing primers.
. Plate 293T cells in #10 cm tissue culture dishes and let adhere overnight.
1. Plate two plates; one will be harvested for Western blot (Step 3), the other for metabolite
analysis (Step 4).
. Transfect 293T cells with appropriate plasmids with Lipofectamine 2000 according to the man-
ufacturer’s instructions.
1. Note: Prepare separate transfection mixtures for each replicate, then use the same mix-
ture for all plates within that replicate; do not use a single large volume for transfection
mixture for all replicates.





2. Incubate for 3 days.
a. At this point, the matched plates for each replicate will be harvested; one plate for
Western blot analysis (Step 6), the matched plate for GC-MS analysis (Step 7).
3. Note; from this point forward, the analysis of each replicate must be conducted separately
and independently from the other replicates. For example, each replicate should be run
on its own gels.
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. Western blot analysis of methylation status:
1. Acid extraction of histones:
a. Lyse cells in hypotonic lysis buffer for 1.
i. Hypotonic lysis buffer: 10mM HEPES, 10mM KCl, 1.5mM MgCl2, 0.5mM DTT,
#protease inhibitor cocktail
b. Add H2SO4 to 0.2N and incubate at 4˚C overnight with rotation.
c. #Centrifuge samples at 6,500xg for 10min at 4˚C to pellet debris.
d. Precipitate proteins with 33% TCA.
e. Wash with acetone.
f. Resuspend in de-ionized water.
2. *#Quantify protein concentration using a Bradford Assay.
3. #Load ~ 50 mg of protein per well and separate proteins on a 10% NuPAGE 4-12% gra-
dient gel.
4. #Transfer to nitrocellulose membrane using an XCell II blot module at 25 V for 1-2 hr
(start at 100 mA per gel).
5. *Perform a Ponceau stain and image to confirm transfer of proteins.
a. Wash out Ponceau.
6. Block membrane for #1 hr in 5% non-fat milk in PBS with 0.5% Tween-20.
7. Incubate with primary antibodies #diluted in TBST + 1% nonfat milk at 4˚C overnight.








h. Anti-H3 (loading control)
i. #Each antibody will have its own gel run. Membranes will not be stripped and
reprobed.
8. Wash membrane #twice with TBST for a total of 20 min.
a. Incubate with HRP-conjugated secondary antibodies #diluted in TBST for 1 hr at
room temperature. #*Use manufacturer recommended dilutions.
9. Wash three times with TBST.
10. Detect signal #using ECL plus according to the manufacturer’s instructions.
11. Quantify band intensities with ImageJ.
a. Normalize methylation band intensities to total H3.
b. Divide normalized band intensities by the vector control band intensity.
. Gas chromatography-mass spectrometry analysis of 2HG levels. Note; the data in the original
paper and the methodology are derived from Figueroa and colleagues (Figueroa et al.,
2010).
1. Gently remove culture medium from cells 3 days after transfection, #wash cells quickly
three times with 2 ml ice-cold PBS, and add #0.5 ml ice-cold 80% methanol containing
20 mM L-norvaline per well of a 6-well plate to the cells.
a. #Quantify protein concentration using the #Bio-Rad Quick Start Bradford Assay.
2. Incubate 20 min at -80˚C.
3. Centrifuge at 14000xg for 20 min at 4˚C.
a. #Counter-extract samples with chloroform to remove nonpolar metabolites.
4. Collect supernatant and dry using a #MiVac.
5. Redissolve dried extracts in #60 mL of a 1:1 mixture of acetonitrile and N-methyl-N-tert-
butyldimethylsilyltrifluoroacetamide (MTBSTFA).
6. Heat the samples for 75 min at 70˚C.
7. GC-MS analysis:
a. #A Shimadzu QP2010 Plus GC-MS is programmed with an injection temperature of
250˚C, injection split ratio 1/10, with injection volume 0.3-1 ml. GC oven temperature
starts at 130˚C for 4 min, rising to 243˚C at 6˚C/min and to 280˚C at 60˚C/min with a
final hold at this temperature for 2 min. GC flow rate with helium carrier gas was 50
cm/s. The GC column used is a 15 m x 0.25 mm x 0.25 mm Rxi-5ms (Restek). GC-MS
interface temperature is 300˚C and (electron impact) ion source temperature is
200˚C, with 70 V/ 70 mA ionization voltage/ current. The mass spectrometer is set to
scan m/z range 150-600, with ~1 kV detector sensitivity (modified as necessary).
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8. *#In parallel to the sample, run a standard curve of known amounts of 2HG.
9. Confirm and *#quantify 2HG metabolite peak using standard curve.
10. Analyze and *#quantify 2HG and glutamate signal (identified by elution time and mass
fragment pattern) intensities by integration of peak areas.
. Repeat independently from Step 4 onwards an additional five times.
Deliverables
. Data to be collected:
 Sequence files and agarose gel images confirming vector identity
 Full gel images of western blots with ladder (as seen in Figure 1B)
& Images of Ponceau stained membranes
 Quantification of band intensities (as seen in Supplemental Figure 1A)
 GC-MS data
 Quantification of signal intensities of 2HG and glutamate (as seen in Figure 1B)
Confirmatory analysis plan
. Statistical Analysis of the Replication Data:
Note: At the time of analysis we will calculate Pearson’s r to check for correlation between
the six dependent variables, normalized intensities measured for each of the histone lysine
methylations, for the Western blot data. We will also perform the Shapiro-Wilk test and gen-
erate a quantile-quantile plot to assess the normality of the Western blot data and 2HG/glu-
tamate ratios. We will also perform Levene’s test to assess homoscedasticity. If the data
appear skewed we will perform a log transformation in order to proceed with the proposed
statistical analysis. If the log transformation does not result in similar variance across groups,
we will perform the equivalent non-parametric test listed in Power Calculations for this
protocol.
 Western blot:
& MANOVA (six dependent variables are the normalized intensities for each of the
histone lysine methylations; four independent variables are the IDH1 and IDH2 var-
iants (all normalized to vector) with the following planned comparisons using Bon-
ferroni’s correction:
. Wild-type IDH1 compared to IDH1R132H, for H3K9me2.
. Wild-type IDH2 compared to IDH2R172K, for H3K9me2.
 2HG/glutamate ratios:
& One-way ANOVA (one dependent variable is the 2HG/glutamate ratio; four inde-
pendent variables are the IDH1 and IDH2 variants) with the following planned com-
parisons using Bonferroni’s correction:
& IDH1WT compared to IDH1R132H
& IDH2WT compared to IDH2R172K
. Meta-analysis of original and replication attempt effect sizes:
 For Western blot:
& The replication attempt will perform the statistical analysis listed above, compute
the effects sizes, compare them against the reported effect size in the original
paper and use a meta-analytic approach to combine the original and replication
effects, which will be presented as a forest plot.
 For 2HG/glutamate ratios:
& The replication data will be presented as a mean with 95% confidence intervals and
will include the original data point, calculated directly from the representative
image, as a single point on the same plot for comparison.
. Additional exploratory analysis:
 Correlation analysis (Pearson’s r) of each of the six relative histone methylation levels to
2HG/glutamate levels using Bonferroni ‘s correction (as seen in Supplemental Figure 1B).
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Known differences from the original study
. The replication attempt will quantify total amounts of 2HG in addition to the ratio of 2HG to
glutamate.
. Aspects of the Western blot protocol are provided by the replicating lab; complete details of
the original protocol were unavailable.
Provisions for quality control
All data obtained from the experiment - raw data, data analysis, control data and quality control
data - will be made publicly available, either in the published manuscript or as an open access data-
set available on the Open Science Framework (https://osf.io/vfsbo/).
. Sequence files and agarose gel images confirming vector identity and integrity
. Ponceau stains confirming protein transfer to membranes
. STR profiling and mycoplasma testing results
Protocol 2: Examining the effects of mutations in IDH2 on
differentiation of 3T3-L1 cells
This protocol describes how to induce the differentiation of 3T3-L1 cells into adipocytes, which
involves extensive chromatin remodeling, after transfection with wild type and mutant forms of IDH2
and assess the level of differentiation by Oil-Red-O staining, as seen in Figure 2A and B, and adipo-
cyte marker expression, as seen in Figure 2D.
Sampling
. This experiment will use 5 biological replicates for a minimum power of 80%. The metabolite
data is qualitative, thus to determine an appropriate number of replicates to initially perform,
sample sizes based on a range of potential variance was determined.
 See Power Calculations for details.
. Each experiment will consist of three cohorts:
 Cohort 1: 3T3-L1 cells transduced with vector
 Cohort 2: 3T3-L1 cells transduced with wild-type IDH2
 Cohort 3: 3T3-L1 cells transduced with IDH2R172K
. Each cohort will have 5 plates per biological replicate:
 One plate will be used to assess IDH2 expression by Western blot.
 The second plate will be used to assess intracellular levels of 2HG.
 The third plate will be assessed for adipogenesis by Oil-Red-O staining.
 The fourth and fifth plates will have mRNA harvested for qRT-PCR analysis.
Materials and reagents
Reagent Type Manufacturer Catalog # Comments
Isobutylmethylxanthine Inhibitor Sigma I5879 Original cat# unspecified
Dexamethasone Chemical Sigma D4902 Original cat# unspecified
Insulin Growth factor Sigma I3536 Original cat# unspecified
Troglitazone Chemical Sigma T2573 Original cat# unspecified
pCL-Eco helper plasmid Nucleic acid Addgene 12371 Original source unspecified
293T cells Cell line ATCC CRL-3216 Original source unspecified
3T3-L1 cells Cell line ATCC CL-173 Original source unspecified
Puromycin Chemical Life Technologies A11138-02 Original unspecified
RIPA buffer Cell culture Millipore 20188 Original source unspecified
Nitrocellulose membrane Western blot reagent Life Technologies LC2006 Original source unspecified
Continued on next page
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Continued
Reagent Type Manufacturer Catalog # Comments
Ponceau stain Chemical Sigma P7170 Original source unspecified
Rabbit polyclonal anti-IDH1 Antibody ProteinTech 12332-1-AP
Mouse IgG1 monoclonal anti-IDH2 Antibody Abcam Ab55271
HRP-conjugated donkey anti-rabbit secondary Antibody GE Healthcare NA934V
HRP-conjugated sheep anti-mouse secondary Antibody GE Healthcare NA931V
Oil-Red-O Chemical Sigma O1391 Original source unspecified
paraformaldehyde Chemical Tousimis 1008A Original source unspecified
6-well tissue culture plates Labware Sarstedt 83.1839 Original unspecified
XtremeGene HP reagent Cell culture Roche 06366244001 Original unspecified
DMEM Cell culture Corning 15013 CV Replaces original from
Invitrogen
FBS Cell culture CellGro 10437-028 Original cat # unspecified
OPTI-MEM Cell culture Life Technologies 31986070 Original unspecified
0.45 mm low binding syringe filter Labware Millipore SLHV013SL Original unspecified
Endo-free maxiprep kit Kit Qiagen 12362 Original unspecified
Protein Concentration Assay;
Quick Start Bradford Assay
Reporter assay Bio-Rad 500-0205 Original unspecified
Spectrophotometer Instrument Beckman Coulter DU800 Original unspecified
TRIzol Chemical Invitrogen 15596-018 Original cat# unspecified
SuperScript II reverse transcriptase Kit Invitrogen 18064-014 Original cat# unspecified
7900HT Sequence Detection System Instrument Applied Biosystems
Pparg Taqman assays; Hs00234592_m1 Nucleic acid Applied Biosystems Cat. # 4351372 Original assay unspecified
Cebpa Taqman assays; Hs00269972_s1 Nucleic acid Applied Biosystems Cat. # 4331182 Original assay unspecified
Adipoq Taqman assays; Hs00605917_m1 Nucleic acid Applied Biosystems Cat. # 4331182 Original assay unspecified
18S rRNA Taqman assays; Hs99999901_s1 Nucleic acid Applied Biosystems Cat. # 4331182 Original assay unspecified
Procedure
Note: 3T3-L1 and 293T cells are maintained in DMEM with 10% FBS at 37˚C/5% CO2 .All cells will be
sent for STR profiling and mycoplasma testing. pLPC (empty vector), pLPC-IDH2, and pLPC-
IDH2R172K are generated in Protocol 1.
. Generate vector and IDH2 wild type and mutant expressing retroviruses.
1. #Transfect 293T cells with pCL-Eco helper plasmid and vector or IDH2 vectors.
a. Spot virus construct in 6 well plates at 1000 ng/well.
b. Perform X-tremeGeneHP reverse transfection as follows:
i. Make the helper plasmid mix; 700 ng/well.
ii. Add 4 mL of XtremeGene HP to 400 mL OPTI-MEM.
. Mix by light tapping.
iii. Mix together the helper plasmids with the XtremeGeneHP reagent and OPTI-
MEM.
iv. Add 400 mL of the mix to each well and incubate for at least 30 min at room
temperature.
v. Meanwhile, resuspend 293T cells in DMEM + 10% FBS at 1.2x106 cells/ml.
vi. Add 1600 mL of cells to each well.
2. #24 hr later, replace media (2 ml total).
3. #48 hr post transfection, collect supernatant from each well.
a. Centrifuge at 500xg for 10 min at room temperature to pellet debris.
b. Filter supernatant through a 0.45 mm syringe filter, aliquot and store at -80˚C.
. Transduce 3T3-L1 cells with viral supernatant.
1. #Seed cells in 6-well plates and incubate overnight.
a. Cells should be 50-60% confluent the next day.
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2. #Add viral supernatant to medium.
a. Supernatant will be added at varying concentrations to determine optimal transduc-
tion efficiency; 1:5 to 1:10 – 150 to 300 mL per well.
3. #Adjust media volume to 1.4 ml per well.
4. #Add polybrene in 100 mL of media into each well for a final concentration of 8 mg/ml.
5. #Spinoculate by spinning at 1000xg for 60 min at room temperature.
a. Incubate overnight.
6. #Change media to remove viral transduction media.
a. Replace with fresh media.
7. Grow cells with 2.5 mg/ml puromycin for 7 days to select for stable expression of either
wild-type or mutant IDH2.
a. Maintain cells in puromycin.
b. Also treat a non-transduced well of 3T3-L1 cells as a control showing susceptibility
to puromycin.
c. Split each biological replicate into 5 plates for the four assays being performed.
i. Plate 1 is for Western blot
ii. Plate 2 is for GC-MS
iii. Plate 3 is for Oil-Red-O staining (harvested 7 days after differentiation)
iv. Plate 4 and 5 are for qRT-PCR (harvested 0 and 4 days after differentiation)
. Generate whole cell lysates from the first plate of each cohort:
1. Lyse cells and sonicate in RIPA buffer.
a. RIPA buffer: 1% sodium deoxycholate, 0.1% SDS, 1% Triton X-100, 0.01 M Tris pH
8.0 and 0.14 M NaCl
b. #Sonicate for 1 min, at 180 watts with rounds of 10 sec on/10 sec off. Keep sample
on ice during sonication.
2. Centrifuge lysates at 14000xg for 10 min at 4˚C.
3. Collect supernatant and measure total protein concentration #using a Bradford assay.
4. Perform Western blot as outlined in Protocol 1 Step 6 using the following primary anti-
bodies *at the manufacturer’s recommended dilution:
a. Anti-IDH1
b. Anti-IDH2
. Harvest the second plate for metabolite analysis by mass spectrometry as described in Proto-
col 1 Step 4.
. Induce 3T3-L1 cells to differentiate into adipocytes.
1. Incubate cells for 2 days with a differentiation cocktail composed of 0.5 mM isobutylme-
thylxanthine, 1 mM dexamethasone, 5 mg/ml insulin and 5 mM troglitazone supplement-
ing the standard media.
2. After 3 days, maintain cells with 5 mg/ml insulin until harvested.
. After 7 days of differentiation, assess adipogenesis by Oil-Red-O staining in the third plate
from each cohort.
1. Wash cells in PBS and fix in 3% paraformaldehyde for 20 min at room temperature.
2. Wash cells with de-ionized water.
3. Stain with Oil-Red-O solution according to the manufacturer’s protocol.
4. Image stained wells by brightfield microscopy and *quantify Oil-Red-O staining by
extracting oil-red-o in isopropanol and reading absorbance at 500 nm.
. Harvest fourth plate for RNA extraction at Day 0 of differentiation and the fifth plate at Day 4
of differentiation and perform qRT-PCR to assess expression levels of adipocyte markers at
each time point.
1. Harvest cells and extract RNA using TRIzol according to the manufacturer’s instructions.
2. Reverse transcribe RNA and synthesize cDNA using SuperScript II reverse transcriptase
according to the manufacturer’s protocol.
a. Assess purity and concentration of RNA and cDNA spectrophotometrically; record
A260/A280 and A260/A230 ratios.
3. Perform qPCR on a 7900HT Sequence Detection system using Taqman gene expression




d. 18S rRNA for normalization.
i. *Primers sequences and PCR cycling conditions will be optimized.
. Repeat independently from Step 2 onwards an additional four times.
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Deliverables
. Data to be collected:
 Whole gel images of Western blots with ladder (as seen in Figure 2A)

*Densitometric quantification of bands
& Also normalized to the loading control.
 Images of wells stained with Oil-Red-O (as seen in Figure 2B)

*Quantification of Oil-Red-O levels for each cohort
 All raw qRT-PCR data
 Graph of gene expression over time for each of the three adipocyte markers (as seen in
Figure 2D)
Confirmatory analysis plan
. Statistical Analysis of the Replication Data:
Note: At the time of analysis we will calculate Pearson’s r to check for correlation between
the three dependent variables, normalized gene expression for each of the adipocyte
markers, for the qRT-PCR data. We will also perform the Shapiro-Wilk test and generate a
quantile-quantile plot to assess the normality of the qRT-PCR data and 2HG/glutamate ratios.
We will also perform Levene’s test to assess homoscedasticity. If the data appears skewed
we will perform a log transformation in order to proceed with the proposed statistical analy-
sis. If this is not possible we will perform the equivalent non-parametric test listed in Power
Calculations for this protocol.
 Western Blot:
& Confirmatory; no analysis performed
 2HG/glutamate ratio:
& One-way ANOVA (one dependent variable is the 2HG/glutamate ratio; three inde-
pendent variables are the vector and IDH2 variants) with the following planned
comparison using Fisher’s LSD correction:
. IDH2R172Kcompared to IDH2WT
 qRT-PCR:
& One-way MANOVA (three dependent variables are the normalized gene expression
of each of the adipocyte markers on day 4; three independent variables are the
vector and IDH2 variants) with the following planned comparisons using Bonferro-
ni’s correction:
. IDH2R172compared to vector for each gene (three comparisons total)
. IDH2R172Kcompared to IDH2WT for each gene (three comparisons total)
. Meta-analysis of original and replication attempt effect sizes:
 For qRT-PCR:
& The replication attempt will perform the statistical analysis listed above, compute
the effects sizes, compare them against the reported effect size in the original
paper and use a meta-analytic approach to combine the original and replication
effects, which will be presented as a forest plot.
 For 2HG/glutamate ratios:
& The replication data will be presented as a mean with 95% confidence intervals and
will include the original data point, calculated directly from the representative
image, as a single point on the same plot for comparison.
. Additional exploratory analysis:
 Oil-Red-O staining:
& One-way ANOVA (one dependent variable is the A500 readings; three independent
variables are the vector and IDH2 variants) with the following planned comparison
using Fisher’s LSD correction:
. IDH2R172K compared to IDH2WT
Richarson et al. eLife 2016;5:e10860. DOI: 10.7554/eLife.10860 10 of 25
Registered report Human biology and medicine
Known differences from the original study
. Aspects of the Western blot protocol are provided by the replicating lab; complete details of
the original protocol were unavailable.
. Aspects of the viral production protocol are adapted from the replicating lab’s in-house
protocol.
. Viral supernatant will be collected only at 48 hr post-transection and will not be com-
bined with viral supernatant collected at 72 hr.
. In addition to imaging Oil-Red-O stained plates, the replication attempt will quantify the
amount of Oil-Red-O staining spectrophotometrically.
Provisions for quality control
All data obtained from the experiment - raw data, data analysis, control data and quality control
data - will be made publicly available, either in the published manuscript or as an open access data-
set available on the Open Science Framework (https://osf.io/vfsbo/).
. Sequence files and agarose gel images confirming vector identity and integrity
. Ponceau stains confirming protein transfer to membranes
. STR profiling and mycoplasma testing results
. Absorbance data for RNA and cDNA
Protocol 3: Assessing the role of KDM4C on differentiation of 3T3-L1
cells
This protocol describes how to treat 3T3-L1 cells with an siRNA against the histone demethylase
KDM4C, whose activity is inhibited by 2HG, and assess the effect of loss of KDM4C activity on meth-
ylation and differentiation, as seen in Figure 4D and Supplemental Figure 8.
Sampling
. This experiment will be repeated 3 times for a minimum power of 80%. The Western blot
data is qualitative, thus to determine an appropriate number of replicates to initially perform,
sample sizes based on a range of potential variance was determined.
 See Power calculations for details.
. Each experiment consists of five cohorts:
 Cohort 1: 3T3-L1 cells treated with scramble control siRNAs
 Cohort 2: 3T3-L1 cells treated with siRNAs #1 against KDM4C
 Cohort 3: 3T3-L1 cells treated with siRNAs #2 against KDM4C
 Cohort 4: 3T3-L1 cells treated with siRNAs #3 against KDM4C
 Cohort 5: untreated 3T3-L1 cells [additional control]
. Each cohort is induced to differentiate, followed by:





 Assessment of differentiation by Oil-Red-O staining
Materials and reagents
Reagent Type Manufacturer Catalog # Comments
3T3-L1 cells Cell line ATCC CL-173 Original source unspecified
DMEM Cell culture Corning 15013 CV Replaces original from Invitrogen
FBS Cell culture CellGro 10437-028 Original cat # unspecified
Continued on next page
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Continued
Reagent Type Manufacturer Catalog # Comments
KDM4C siRNA #1 Nucleic acid Synthesis left to the discretion of the replicating lab
KDM4C siRNA #2 Nucleic acid Synthesis left to the discretion of the replicating lab
KDM4C siRNA #3 Nucleic acid Synthesis left to the discretion of the replicating lab
Scrambled control siRNA Nucleic acid Dharmacon D-001810-01-20
Lipofectamine RNAiMAX Cell culture Invitrogen 13778-030 Original cat# unspecified
isobutylmethylxanthine Inhibitor Sigma I5879 Original cat# unspecified
dexamethasone Chemical Sigma D4902 Original cat# unspecified
insulin Growth factor Sigma I3536 Original cat# unspecified
Troglitazone Chemical Sigma T2573 Original cat# unspecified
RIPA buffer Cell culture Millipore 20188 Original source unspecified
Nitrocellulose membrane Western blot reagent Life Technologies LC2006 Original source unspecified
Ponceau stain Chemical Sigma P7170 Original unspecified
Mouse IgG2a monoclonal anti-b-actin Antibody Sigma A5316
Rabbit IgG monoclonal anti-H3 Antibody Cell Signaling Technology 4499
Rabbit polyclonal anti-H3K9me3 Antibody Abcam Ab8898
Rabbit polyclonal anti-KDM4C Antibody Abcam Ab85454
Oil-Red-O Chemical Sigma O1391 Original source unspecified
paraformaldehyde Chemical Tousimis 1008A Original source unspecified
Procedure
Note: 3T3-L1 cells are maintained in DMEM with 10% FBS at 37˚C/5% CO2. All cells will be sent for
STR profiling and mycoplasma testing.
. Transfect with 3T3-L1 cells with siRNAs against KDM4C:
1. Plate out equal densities of single cell suspensions of 3T3-L1 cells in #6-well plates.
a. *Optimize the number of cells to plate per well.
b. Plate out two plates per siRNA pool (control vs. siKDM4C).
i. One will be harvested on Day 3 of differentiation for Western blot analysis.
ii. One will be used on Day 7 of differentiation for Oil-Red-O analysis.
2. Transfect with the following siRNAs at a final concentration of 40 nM using Lipofectamine






3 Sense 5’-GAGGAGUU UCGGGAGUUCAACAAAU-3’
Antisense 5’-AUUUGUUGAACUCCCGAA ACUCCUC-3’
a. Transfect control wells with a scrambled control siRNA.
b. Also plate control wells with no transfection.
3. Incubate for 3 days.
. Induce differentiation of control siRNA and antisense siRNA transduced 3T3-L1 cells as speci-
fied in Protocol 2 Step 6.
. 3 days after differentiation, harvest one plate from each treatment and prepare whole cell
lysates as specified in Protocol 2 Step 7.
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2. Quantify band intensities with ImageJ.
a. Normalize H3K9me3 band intensities to total H3.
b. Normalize KDM4C band intensities to ß-actin.
. At Day 7 of differentiation, assess level of differentiation by Oil-Red-O staining as specified in
Protocol 2 Step 8.
1. Image wells and quantify Oil-Red-O expression.
. Repeat experiment an additional two times.
Deliverables
. Data to be collected:
 Whole gel images of all Western blots with ladder (as seen in the top of Figure 4D)
 Images of Oil-Red-O stained wells (as seen in the bottom half of Figure 4D)
. Quantification of Oil-Red-O staining at Day 7 of differentiation (compare to Supplemental
Figure 8B)
Confirmatory analysis plan
. Statistical Analysis of the Replication Data:
Note: At the time of analysis we will calculate Pearson’s r to check for correlation between
the two dependent variables, normalized intensities measured for KDM4C and H3K9me3, for
the Western blot data. We will also perform the Shapiro-Wilk test and generate a quantile-
quantile plot to assess the normality of the Western blot and Oil-Red-O data. We will also
perform Levene’s test to assess homoscedasticity. If the data appears skewed we will per-
form a log transformation in order to proceed with the proposed statistical analysis. If this is
not possible we will perform the equivalent non-parametric test listed in Power Calculations
for this protocol.
 Quantification of Oil-Red-O staining:
& One way ANOVA (one dependent variable is the A500 readings; four independent
variables are the control and three KDM4C siRNA sequences) with the following
planned comparisons using Bonferroni’s correction:
. Control siRNA compared to KDM4C siRNA #1
. Control siRNA compared to KDM4C siRNA #2
. Control siRNA compared to KDM4C siRNA #3 [additional exploratory analysis]
 Western blot:
& One-way MANOVA (two dependent variables are the normalized intensities mea-
sured for KDM4C and H3K9me3; four independent variables are the control and
three KDM4C siRNA sequences) with the following planned comparisons using
Bonferroni’s correction:
. H3K9me3 levels:
 Control siRNA compared to KDM4C siRNA #1
 Control siRNA compared to KDM4C siRNA #2
 Control siRNA compared to KDM4C siRNA #3
. KDM4C levels (QC):
 Control siRNA compared to KDM4C siRNA #1
 Control siRNA compared to KDM4C siRNA #2
 Control siRNA compared to KDM4C siRNA #3
. Meta-analysis of original and replication attempt effect sizes:
 Oil-Red-O staining for siRNA #1 and #2:
& This replication attempt will perform the statistical analysis listed above, compute
the effects sizes, compare them against the reported effect size in the original
paper and use a meta-analytic approach to combine the original and replication
effects, which will be presented as a forest plot.
. There is no originally reported data from siRNA #3, therefore it will not be
included.
 Western Blot:
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& The replication data will be presented as a mean with 95% confidence intervals and
will include the original data point, calculated directly from the representative
image, as a single point on the same plot for comparison.
Known differences from the original study
The replication will perform the Oil-Red-O quantification for all three siRNAs, not just #1 and #2
as presented in Supplemental Figure 8.
Provisions for quality control
All data obtained from the experiment - raw data, data analysis, control data and quality control
data - will be made publicly available, either in the published manuscript or as an open access data-
set available on the Open Science Framework (https://osf.io/vfsbo/).
. Ponceau stains confirming protein transfer to membranes
. STR profiling and mycoplasma testing results
Power calculations
Note: details of all power calculations can be found at https://osf.io/rb32p/
Protocol 1
Summary of original data
Note: data estimated from published figures.
Supplemental Figure 1: normalized WB band intensity
(normalized to Vector) Mean SD N
IDH1WT H3K9me2 1.7 0.8 3
H3K9me3 1 0.2 3
K3K4me3 1.2 0.6 3
H3K27me3 0.4 0.3 3
H3K36me3 1.2 0.4 3
H3K27me2 0.8 0.4 3
IDH1R132H H3K9me2 7.9 2.5 3
H3K9me3 4.1 1.2 3
K3K4me3 3.4 0.8 3
H3K27me3 2.5 0.5 3
H3K36me3 1.7 0.8 3
H3K27me2 4.7 2.5 3
IDH2WT H3K9me2 3.2 1.1 3
H3K9me3 2.1 1.2 3
K3K4me3 1.9 0.3 3
H3K27me3 1.9 0.8 3
H3K36me3 1.4 0.4 3
H3K27me2 1.5 0.9 3
IDH2R172K H3K9me2 11.4 3.8 3
H3K9me3 4.9 1.6 3
K3K4me3 4 1.4 3
H3K27me3 3.6 1.6 3
H3K36me3 1.8 0.7 3
H3K27me2 5.4 3.7 3
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. Western blot; Figure 1B/Supplemental Figure 1A:
Note: Since we do not have the raw data, we were unable to perform power calculations
using a MANOVA. We are approximating sample sizes with corrected one-way ANOVAs for
each DV (normalized histone methylations).
. Bonferroni-corrected one-way ANOVAs (one per DV) followed by Bonferroni corrected
planned comparisons:
& Wild-type IDH1 compared to IDH1R132H, collapsed across all histone lysine
methylations.
& Wild-type IDH2 compared to IDH2R172K, collapsed across all histone lysine
methylations.
. Note: Only H3K9me2 is being included since this is the histone modification
with the largest effect size reported. A correlation among all the histone methyl-
ations will also be performed prior to performing the proposed analysis plan.
. 2HG/glutamate ratios; Figure 1B:
 One-way ANOVA followed by Bonferroni-corrected pairwise comparisons for the
following:
& IDH1WT compared to IDH1R132H, for H3K9me2
& IDH2WT compared to IDH2R172K, for H3K9me2
Power calculations
. Power calculations were performed using R software (version 3.2.2) (R Core Team, 2015)
and G*Power (version 3.1.7) (Faul et al., 2007)
. Partial h2 calculated as in Lakens (2013)
. Western blot calculations:
. Note: Due to the large variance, these parametric tests are only used for comparison pur-
poses. The sample size is based on the non-parametric tests also listed. For the ANOVA
a Kruskal-Wallis would be performed as the non-parametric alternative, which would
require an ~15% increase in sample size calculated for the parametric test listed.
One-way ANOVA: a=0.00833, 4 groupsa
DV F(3,8) Partial h2 Effect size f A priori power Total Sample Size
H3K9me2 10.486 0.79726 1.98302 92.1%1 121
H3K9me3 7.0274 0.72492 1.62335 96.4%1 161
H3K4me3 6.6197 0.71284 1.57556 95.1%1 161
H3K27me3 6.0339 0.69351 1.50423 92.7%1 161
H3K36me3 0.6276 0.19051 1.06125 90.2% 24
H3K79me2 3.0033 0.52969 1.079842 80.0%2 24
1 With 6 samples per group (24 total), achieved power is 99.9%.
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2 Since the original effect size will not be detectable with the proposed sample size, this is the effect size that can
be detected at 80% power with the given sample size. The original effect size was 0.48512.
Planned contrasts; two-tailed t-test: a=0.004167
Group 1 Group 2 Effect size d A priori power n/group
IDH1WT IDH1R132H 3.34039 84.9%1 51
IDH2WT IDH2R172K 2.93138 87.3% 6
Planned contrasts; two-tailed Wilcoxon-Mann-Whitney: a=0.025
Group 1 Group 2 Effect size d A priori power n/group
IDH1WT IDH1R132H 3.34039 80.9%2 52
IDH2WT IDH2R172K 2.93138 84.0% 6
1 With 6 samples per group, achieved power is 95.3%.
2 With 6 samples per group, achieved power is 93.4%.
. 2HG/glutamate ratio calculations:
. Note: The original data does not indicate the error associated with multiple biological
replicates. To identify a suitable sample size, power calculations were performed using
different levels of relative variance.
2%; one-way ANOVA: a=0.05, 4 groups
F(3,8) Partial h2 Effect size f A priori power Total Sample Size
7240.7 0.99963 52.11901 99.9% 8
Planned comparisons; 2-tailed t-test: a=0.025
Group 1 versus Group 2 Effect size d A priori power n per group
IDH1WT IDH1R132H 63.6182 99.9% 2
IDH2WT IDH2R172H 69.6606 99.9% 2
15%; one-way ANOVA: a=0.05, 4 groups
F(3,8) Partial h2 Effect size f A priori power Total Sample Size
128.72 0.97970 6.94772 99.9% 8
Planned comparisons; 2-tailed t-test: a=0.025
Group 1 versus Group 2 Effect size d A priori power n per group
IDH1WT IDH1R132H 8.48242 83.5% 2
IDH2WT IDH2R172H 9.28808 88.4% 2
28%; one-way ANOVA: a=0.05, 4 groups
F(3,8) Partial h2 Effect size f A priori power Total Sample Size
36.942 0.93268 3.72201 99.9% 8
Planned comparisons; 2-tailed t-test: a=0.025
Group 1 versus Group 2 Effect size d A priori power n per group
IDH1WT IDH1R132H 4.54415 92.4% 3
IDH2WT IDH2R172H 4.97576 95.9% 3
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40%; one-way ANOVA: a=0.05, 4 groups
F(3,8) Partial h2 Effect size f A priori power Total Sample Size
18.102 0.87160 2.60542 96.0% 8
Planned comparisons; 2-tailed t-test: a=0.025
Group 1 versus Group 2 Effect size d A priori power n per group
IDH1WT IDH1R132H 3.18091 89.6% 4
IDH2WT IDH2R172H 3.48303 94.2% 4
In order to produce quantitative replication data, we will run the experiment six times. Each time
we will quantify the 2HG/glutamate ratio. We will determine the standard deviation across the bio-
logical replicates and combine this with the reported value from the original study to simulate the
original effect size. We will use this simulated effect size to determine the number of replicates nec-
essary to reach a power of at least 80%. We will then perform additional replicates, if required, to
ensure that the experiment has more than 80% power to detect the original effect.
Protocol 2
Summary of original data
Note: data estimated from published figures.





Figure 2D: Relative expression of adipocyte markers
Pparg Mean SD N
Vector Day 0 1.45 0.823 3
Day 4 13.992 0.816 3
IDH2WT Day 0 2.521 1.076 3
Day 4 10.966 0.879 3
IDH2R172K Day 0 1.134 0.823 3
Day 4 4.223 0.941 3
Cebpa Mean SD N
Vector Day 0 1.123 0.421 3
Day 4 3.053 1.188 3
IDH2WT Day 0 1.93 0.456 3
Day 4 4.807 0.565 3
IDH2R172K Day 0 0.667 0.491 3
Day 4 0.246 0.21 3
Adipoq Mean SD N
Continued on next page
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Vector Day 0 0 58.621 3
Day 4 572.414 193.103 3
IDH2WT Day 0 0 58.621 3
Day 4 448.276 86.207 3
IDH2R172K Day 0 0 58.621 3
Day 4 41.379 27.586 3
Test family
. 2HG/glutamate ratios; Figure 2A bottom:
 One way ANOVA followed by Fisher’s LSD for the following comparison:
& IDH2WT vs. IDH2R172K
. qRT-PCR; Figure 2D:
Note: Since we did not have the raw data, we were unable to perform power calculations
using a MANOVA. We are approximating the sample sizes with corrected one-way ANOVAs
for each DV (gene).
 Bonferroni-corrected one-way ANOVAs (one per gene) followed by Bonferroni corrected
comparisons for Day 4 timepoints:
& IDH2R172Kcompared to vector for each gene (3 comparisons total)
& IDH2R172Kcompared to IDH2WT for each gene (3 comparisons total)
Power calculations
. Power calculations were performed using R software (version 3.2.2) (R Core Team, 2015)
and G*Power (version 3.1.7) (Faul et al., 2007)
. Partial h2 calculated as in Lakens (2013)
. 2HG/glutamate ratios:
 Note: The original data does not indicate the error associated with multiple biological
replicates. To identify a suitable sample size, power calculations were performed using
different levels of relative variance.
2%; one-way ANOVA: a=0.05, 3 groups
F(2,6) Partial h2 Effect size f A priori power Total Sample Size
7214.5 0.99958 49.0188 99.9% 6
Planned comparisons; two-tailed t-test: a=0.05
Group 1 versus Group 2 Effect size d A priori power n per group
IDH2R172H IDH2WT 84.9383 99.9% 2
15%; one-way ANOVA: a=0.05, 3 groups
F(2,6) Partial h2 Effect size f A priori power Total Sample Size
128.26 0.97715 6.53866 99.9% 6
Planned comparisons; two-tailed t-test: a=0.05
Group 1 versus Group 2 Effect size d A priori power n per group
IDH2R172H IDH2WT 11.3252 99.8% 2
28%; one-way ANOVA: a=0.05, 3 groups
F(2,6) Partial h2 Effect size f A priori power Total Sample Size
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36.809 0.92464 3.50285 98.5% 6
Planned comparisons; two-tailed t-test: a=0.05
Group 1 versus Group 2 Effect size d A priori power n per group
IDH2R172H IDH2WT 6.06704 84.2% 2
40%; one-way ANOVA: a=0.05, 3 groups
F(2,6) Partial h2 Effect size f A priori power Total Sample Size
18.036 0.85739 2.45194 85.1% 6
Planned comparisons; two-tailed t-test: a=0.05
Group 1 versus Group 2 Effect size d A priori power n per group
IDH2R172H IDH2WT 4.24688 96.6% 3
In order to produce quantitative replication data, we will run the experiment five times. Each time
we will quantify the 2HG/glutamate ratio. We will determine the standard deviation across the bio-
logical replicates and combine this with the reported value from the original study to simulate the
original effect size. We will use this simulated effect size to determine the number of replicates nec-
essary to reach a power of at least 80%. We will then perform additional replicates, if required, to
ensure that the experiment has more than 80% power to detect the original effect.
. qRT-PCR:
 Note: Due to the large variance, these parametric tests are only used for comparison pur-
poses. The sample size is based on the non-parametric tests also listed. For the ANOVA
a Kruskal-Wallis would be performed as the non-parametric alternative, which would
require an ~15% increase in sample size calculated for the parametric test listed.
Pparg
One-way ANOVA: a=0.0167, 3 groups
F(2,6) Partial h2 Effect size f A priori power Total Sample
Size
96.854 0.96996 5.68195 99.5%1 61
Planned comparisons; two-tailed t-test: a=0.0083
Group 1 versus Group 2 Effect size d A priori power n per group
IDH2R172H Vector 11.0921 99.9%2 32
IDH2R172H IDH2WT 7.40559 98.6%2 32
Planned comparisons; two-tailed Wilcoxon-Mann-Whitney: a=0.0083
Group 1 versus Group 2 Effect size d A priori power n per group
IDH2R172H Vector 11.0921 99.9%2 32
IDH2R172H IDH2WT 7.40559 96.9%2 32
1 With 5 samples per group (15 total), achieved power is 99.9%.
2 With 5 samples per group, achieved power is 99.9%.
Cebpa
One-way ANOVA: a=0.0167, 3 groups
F(2,6) Partial h2 Effect size f A priori power Total Sample Size
26.843 0.89947 5.68195 90.5%1 61
Planned comparisons; two-tailed t-test: a=0.0083
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Group 1 versus Group 2 Effect size A priori power n per group
IDH2R172H Vector 3.29048 91.6% 5
IDH2R172H IDH2WT 10.7011 99.9%2 32
Planned comparisons; two-tailed Wilcoxon-Mann-Whitney: a=0.0083
Group 1 versus Group 2 Effect size d A priori power n per group
IDH2R172H Vector 3.29048 89.0% 5
IDH2R172H IDH2WT 10.7011 99.9%2 32
1 With 5 samples per group (15 total), achieved power is 99.9%.
2 With 5 samples per group, achieved power is 99.9%.
Adipoq
One-way ANOVA: a=0.0167, 3 groups
F(2,6) Partial h2 Effect size f A priori power Total Sample Size
15.269 0.83579 2.25603 96.3%1 91
Planned comparisons; two-tailed t-test: a=0.0083
Group 1 versus Group 2 Effect size A priori power n per group
IDH2R172H Vector 3.85001 87.8%2 42
IDH2R172H IDH2WT 6.35752 94.5%3 33
Planned comparisons; two-tailed Wilcoxon-Mann-Whitney: a=0.0083
Group 1 versus Group 2 Effect size d A priori power n per group
IDH2R172H Vector 3.85001 84.0%4 44
IDH2R172H IDH2WT 6.35752 90.8%3 33
1 With 5 samples per group (15 total), achieved power is
99.9%.
2 With 5 samples per group, achieved power is 97.9%.
3 With 5 samples per group, achieved power is 99.9%.
4 With 5 samples per group, achieved power is 96.8%.
Protocol 3
Summary of original data
Note: data estimated from published figures.
Figure 4D and S8A: Western Blot
Band intensity
(normalized to H3)
KDM4C Control siRNA 1
KDM4C siRNA #1 0.50971
KDM4C siRNA #2 0.27671
KDM4C siRNA #3 0.02492
H3K9me3 Control siRNA 1
KDM4C siRNA 0.36952
1 These values were normalized to ß-Actin as seen in Supplemental Figure 8A.
2 These values were normalized to total H3 as seen in Figure 4D. Also there is no data for siRNAs #1 and #2. We
have assumed similar values for siRNA #3 for the purposes of these calculations.
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Supplemental Figure 8B: Oil-Red-O quantification Mean SD N
Control 1.06 0.03 3
siRNA #1 0.42 0.15 3
siRNA #2 0.69 0.09 3
siRNA #31 0.69 0.09 3
1 There is no data for siRNA #3. We have assumed similar values as siRNA #2 for the purposes of these
calculations.
Test family
. Western blot; Figure 4D and S8A:
Note: Since we did not have the raw data, we were unable to perform power calculations
using a MANOVA. We are approximating the sample sizes with corrected one-way ANOVAs
for each DV (normalized protein).
 One-way ANOVAs followed by Bonferroni corrected comparisons:
& H3K9me3 levels in control siRNA compared to each KDM4C siRNA (3 comparisons
total)
& KDM4C levels in control siRNA compared to each KDM4C siRNA (3 comparisons
total)
. Quantification of Oil-Red-O staining; Figure S8B:
 One way ANOVA followed by Bonferroni corrected comparisons:
& Control siRNA compared to KDM4C siRNA #1
& Control siRNA compared to KDM4C siRNA #2
& Control siRNA compared to KDM4C siRNA #3
Power calculations
. Power calculations were performed using R software (version 3.2.2) (R Core Team, 2015)
and G*Power (version 3.1.7) (Faul et al., 2007).
. Partial h2 calculated as in Lakens (2013).
. Western Blot
 Note: The original data does not indicate the error associated with multiple biological
replicates. To identify a suitable sample size, power calculations were performed using
different levels of relative variance.
2%; One-way ANOVA: a=0.025, 4 groups a
DV F(3,8) Partial h2 Effect size f Power Total sample
size
H3K9me3 2114.7 0.99874 28.161 99.9% 8
KDM4C 3865.5 0.99931 38.073 99.9% 8
Planned comparisons; two-tailed t-test: a=0.0083
DV Group 1 versus Group 2 Effect size d A priori
power
n per group
H3K9me3 Control KDM4C #1 53.099 99.9% 2
Control KDM4C #2 53.099 99.9% 2
Control KDM4C #3 53.099 99.9% 2
KDM4C Control KDM4C #1 42.407 99.9% 2
Control KDM4C #2 62.552 99.9% 2
Control KDM4C #3 84.335 99.9% 2
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15%; One-way ANOVA: a=0.025, 4 groups
DV F(3,8) Partial h2 Effect size f Power Total sample size
H3K9me3 37.595 0.93377 3.7547 99.2% 8
KDM4C 68.72 0.96264 5.0764 99.9% 8
Planned comparisons; two-tailed t-test: a=0.0083
DV Group 1 versus Group 2 Effect size d A priori power n per group
H3K9me3 Control KDM4C #1 7.0800 97.8% 3
Control KDM4C #2 7.0800 97.8% 3
Control KDM4C #3 7.0800 97.8% 3
KDM4C Control KDM4C #1 5.6543 88.5% 3
Control KDM4C #2 8.3403 99.6% 3
Control KDM4C #3 11.245 99.9% 3
28%; One-way ANOVA: a=0.025, 4 groups
DV F(3,8) Partial h2 Effect size f Power Total sample size
H3K9me3 10.789 0.80182 2.0114 98.7% 12
KDM4C 19.722 0.88089 2.7195 89.2% 8
Planned comparisons; two-tailed t-test: a=0.0083
DV Group 1 versus Group 2 Effect size d A priori power n per group
H3K9me3 Control KDM4C #1 3.7928 86.8% 4
Control KDM4C #2 3.7928 86.8% 4
Control KDM4C #3 3.7928 86.8% 4
KDM4C Control KDM4C #1 3.0291 85.9% 5
Control KDM4C #2 4.4680 95.8% 4
Control KDM4C #3 6.0240 92.1% 3
40%; One-way ANOVA: a=0.025, 4 groups
DV F(3,8) Partial h2 Effect size f Power Total sample size
H3K9me3 5.2868 0.66472 1.4080 80.2% 12
KDM4C 9.6637 0.78373 1.9037 97.6% 12
Planned comparisons; two-tailed t-test: a=0.0083
DV Group 1 versus Group 2 Effect size d A priori power n per group
H3K9me3 Control KDM4C #1 2.6550 87.2% 6
Control KDM4C #2 2.6550 87.2% 6
Control KDM4C #3 2.6550 87.2% 6
KDM4C Control KDM4C #1 2.1204 85.6% 8
Control KDM4C #2 3.1276 88.3% 5
Control KDM4C #3 4.2168 93.3% 4
In order to produce quantitative replication data, we will run the experiment three times. Each
time we will quantify band intensity. We will determine the standard deviation of band intensity
across the biological replicates and combine this with the reported value from the original study to
simulate the original effect size. We will use this simulated effect size to determine the number of
replicates necessary to reach a power of at least 80%. We will then perform additional replicates, if
required, to ensure that the experiment has more than 80% power to detect the original effect.
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. Oil-Red-O staining:
 Note: Due to the large variance, these parametric tests are only used for comparison pur-
poses. The sample size is based on the non-parametric tests also listed. For the ANOVA
a Kruskal-Wallis would be performed as the non-parametric alternative, which would
require an ~15% increase in sample size calculated for the parametric test listed.
One-way ANOVA: a=0.05, 4 groups
F(3,8) Partial eta2 Effect size f Power Total Sample Size
20.939 0.88703 2.8022 97.8%1 81
1 With 3 samples per group (12 total), achieved power is 99.9%.
Planned comparisons; two-tailed Wilcoxon-Mann-Whitney: a=0.0167
Power Calculations
Group 1 Group 2 Effect size d Power n/group
Control KDM4C #1 5.9168 96.9% 3
Control KDM4C #2 5.5156 93.3% 3
Control KDM4C #3 5.5156 93.3% 3
Planned comparisons; two-tailed t-test: a=0.0167
Group 1 Group 2 Effect size d Power n/group
Control KDM4C #1 5.9168 97.7% 3
Control KDM4C #2 5.5156 95.6% 3
Control KDM4C #3 5.5156 95.6% 3
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